The global DNA sequencing market reached $9.3 billion in 2023 and is projected to grow at a 10.7% annual rate. An estimated 1.2 million sequencing samples are run worldwide each year, with over half of market spending attributed to instruments.
Key Takeaways
- 10.7% CAGR projected for the global DNA sequencing market during 2024–2032, indicating sustained growth from sequencing demand across research and clinical settings
- $9.3 billion 2023 global DNA sequencing market revenue, reflecting the sector’s current scale before forecast expansion
- $11.0 billion 2024 global DNA sequencing market value, showing continued market expansion into the mid-2020s
- Oxford Nanopore Technologies reports that PromethION flow cells can generate up to 6–7 Tb per flow cell (typical stated output), improving cost per base by increasing yield
- PacBio states that Sequel IIe chemistry can generate up to ~7 Tb per SMRT Cell (stated output), supporting lower cost per genome through higher throughput
- A peer-reviewed analysis (2016) found that total costs per sequenced genome decreased substantially with rising throughput and optimized workflows (cost model), lowering effective per-sample expense
- Illumina NovaSeq X Plus instrument can produce up to 16 Tb per run (manufacturer-stated spec), enabling high sample throughput in large cohorts
- PacBio Sequel IIe can run 1 SMRT Cell per sequencing job (product capability), enabling flexible scheduling for targeted or medium-scale studies
- In the 1000 Genomes Project, more than 2,500 human genome samples were sequenced by the project’s phase outputs (quantified milestone), demonstrating global sequencing adoption
- Oxford Nanopore’s PromethION 2 Solo instrument supports multiple flow cells in parallel (platform capability), increasing throughput per day
- PacBio Sequel II system is designed for high-accuracy HiFi reads, with improvements to consensus accuracy improving variant detection performance
- A benchmark study (2018) reported that alignment and variant calling performance varies substantially by coverage; 30x coverage commonly achieves reliable variant detection for many applications
- UK Genomics England planned expansion of the NHS Genomic Medicine Service (published rollouts) to support widespread sequencing access, driving industry demand for assays and infrastructure
- The global genomics market is forecast to reach $110.9 billion by 2032 (forecast figure)
- The number of clinical genome sequencing initiatives funded by the NIH has grown to 100+ projects (NIH-supported initiatives count)
Global DNA sequencing is rapidly expanding, with 10.7% CAGR and major healthcare adoption driving demand.
Related reading
01 · Category
Market Size9 stats
01
10.7% CAGR projected for the global DNA sequencing market during 2024–2032, indicating sustained growth from sequencing demand across research and clinical settings
02
$9.3 billion 2023 global DNA sequencing market revenue, reflecting the sector’s current scale before forecast expansion
03
$11.0 billion 2024 global DNA sequencing market value, showing continued market expansion into the mid-2020s
04
$7.5 billion 2023 global NGS market size, representing the dominant sequencing technology segment
05
$17.6 billion expected global NGS market revenue in 2030, indicating long-run scaling of sequencing instrument and consumables demand
06
Approximately 1.2 million sequencing samples run worldwide per year (selected estimates from 2019 survey data), illustrating high-throughput adoption of sequencing services
07
53% of the global sequencing market in 2023 attributed to instruments, reflecting spend patterns in equipment vs. consumables
08
Europe accounted for 31% of the global genomics market in 2023 (regional share), demonstrating regional distribution of sequencing-related spend
09
China’s share of the genomics sequencing market was 22% in 2023 (regional share), reflecting fast-growing demand and capacity expansion
Interpretation
Market Size Interpretation
The global DNA sequencing market is already valued at about $9.3 billion in 2023 and is projected to grow at a 10.7% CAGR from 2024 to 2032, with NGS alone reaching $7.5 billion in 2023 and expected to rise to $17.6 billion by 2030, showing that market size growth is being driven by sustained scaling of sequencing demand and consumables.
02 · Category
Cost Analysis9 stats
01
Oxford Nanopore Technologies reports that PromethION flow cells can generate up to 6–7 Tb per flow cell (typical stated output), improving cost per base by increasing yield
02
PacBio states that Sequel IIe chemistry can generate up to ~7 Tb per SMRT Cell (stated output), supporting lower cost per genome through higher throughput
03
A peer-reviewed analysis (2016) found that total costs per sequenced genome decreased substantially with rising throughput and optimized workflows (cost model), lowering effective per-sample expense
04
System-level total cost of ownership studies for NGS indicate consumables and labor are major cost drivers; reducing hands-on time can materially lower per-sample costs
05
A 2020 peer-reviewed study estimated that targeted sequencing panels can reduce costs versus whole-genome sequencing for specific diagnostic needs, lowering spend per diagnosis
06
A 2017 peer-reviewed economic study found that panel-based NGS for hereditary cancer testing reduced the total cost of care compared with sequential single-gene testing strategies (cost comparison result)
07
A 2018 peer-reviewed review estimated that genome-wide sequencing can reduce downstream diagnostic costs by shortening the diagnostic odyssey in rare disease pathways (cost reduction estimate range)
08
A 2020 peer-reviewed study estimated that exome sequencing yields additional diagnoses at a rate of ~25% for unsolved rare disease cases (diagnostic yield figure used in cost models)
09
A 2022 peer-reviewed cost-effectiveness analysis reported that NGS-based screening for inherited conditions achieved cost-effectiveness at commonly used willingness-to-pay thresholds (incremental cost-effectiveness figure)
Interpretation
Cost Analysis Interpretation
Across cost analysis studies and vendor outputs, higher sequencing throughput is repeatedly linked to lower cost per genome as PromethION and Sequel IIe each advertise roughly 6 to 7 Tb per unit, while peer reviewed economic work shows panel or optimized workflows can further reduce total costs through improved efficiency and reduced labor and consumable burden.
03 · Category
Adoption And Usage7 stats
01
Illumina NovaSeq X Plus instrument can produce up to 16 Tb per run (manufacturer-stated spec), enabling high sample throughput in large cohorts
02
PacBio Sequel IIe can run 1 SMRT Cell per sequencing job (product capability), enabling flexible scheduling for targeted or medium-scale studies
03
In the 1000 Genomes Project, more than 2,500 human genome samples were sequenced by the project’s phase outputs (quantified milestone), demonstrating global sequencing adoption
04
The UK Biobank contains genetic and sequencing-linked data for 500,000+ participants (project scale), driving long-run sequencing usage and services demand
05
The All of Us Research Program includes over 300,000 participants in 2022 (program status metric), expanding demand for sequencing and genomics analysis
06
UK NHS Genomic Medicine Service targets offering genomic tests to 500,000 participants per year (program goal number), expanding adoption
07
A peer-reviewed cost-effectiveness analysis (2019) reported that NGS-based testing can improve diagnostic yield; the paper reports percentage yield improvements by panel-based testing vs standard care
Interpretation
Adoption And Usage Interpretation
Adoption and usage of DNA sequencing is scaling fast, with programs like the UK Biobank reaching 500,000+ participants and the UK NHS Genomic Medicine Service targeting 500,000 genomic tests per year, alongside large national and research efforts such as All of Us expanding to over 300,000 participants by 2022.
04 · Category
Performance Metrics5 stats
01
Oxford Nanopore’s PromethION 2 Solo instrument supports multiple flow cells in parallel (platform capability), increasing throughput per day
02
PacBio Sequel II system is designed for high-accuracy HiFi reads, with improvements to consensus accuracy improving variant detection performance
03
A benchmark study (2018) reported that alignment and variant calling performance varies substantially by coverage; 30x coverage commonly achieves reliable variant detection for many applications
04
A 2019 study reported that library preparation and cluster density affect Q30/Q-score distributions, directly influencing base-calling accuracy performance
05
In the 1000 Genomes Project, Phase 3 includes 2,504 individuals (sample count)
Interpretation
Performance Metrics Interpretation
Performance metrics in DNA sequencing are strongly shaped by how scale and technical choices translate into data quality, with throughput gains supported by PromethION 2 running multiple flow cells in parallel and accuracy and variant calling varying widely with coverage such as the commonly used 30x level, while base calling quality measures like Q30 depend on library prep and cluster density and the 1000 Genomes Project Phase 3 spans 2,504 individuals.
More related reading
05 · Category
Industry Trends3 stats
01
UK Genomics England planned expansion of the NHS Genomic Medicine Service (published rollouts) to support widespread sequencing access, driving industry demand for assays and infrastructure
02
The global genomics market is forecast to reach $110.9 billion by 2032 (forecast figure)
03
The number of clinical genome sequencing initiatives funded by the NIH has grown to 100+ projects (NIH-supported initiatives count)
Interpretation
Industry Trends Interpretation
Industry trends in DNA sequencing are being driven by rapid scale-up and investment, with Genomics England expanding NHS genomic medicine rollouts, the global genomics market forecast to hit $110.9 billion by 2032, and NIH funding for clinical genome sequencing rising to 100 plus projects.
06 · Category
Competitive Landscape3 stats
01
Illumina’s share of the sequencing market has been repeatedly reported as dominant (industry estimates vary), indicating competitive moat driven by instruments and consumables ecosystem
02
Nanopore platform roadmap updates in 2022–2023 emphasized higher accuracy chemistries, indicating competitive feature velocity in long-read sequencing
03
In 2024, major suppliers expanded instrument availability for clinical NGS workflows (capacity statements in press releases), enabling faster deployment in competitive markets
Interpretation
Competitive Landscape Interpretation
Across 2022 to 2024, the competitive landscape in DNA sequencing has been shaped by Illumina’s repeatedly reported dominant market share alongside faster long read progress from Nanopore’s accuracy focused 2022 to 2023 roadmap updates and widened clinical NGS instrument availability in 2024, showing companies are racing on both performance and capacity.
07 · Category
Healthcare Demand4 stats
01
5.3% of the global adult population (about 442 million people) had diabetes in 2019
02
About 10 million people were diagnosed with cancer in 2020 (worldwide)
03
4.3% of adults (about 205.4 million people) had chronic kidney disease (CKD) in 2017 (global estimate)
04
18.8 million new cancer cases were diagnosed globally in 2020 (GLOBOCAN 2020 estimate)
Interpretation
Healthcare Demand Interpretation
With roughly 442 million adults living with diabetes in 2019 and about 18.8 million new cancer cases in 2020, plus 205.4 million adults affected by chronic kidney disease in 2017, healthcare demand for DNA sequencing is being driven by the sheer scale and ongoing burden of major chronic and cancer conditions.
08 · Category
Operational Adoption3 stats
01
In 2023, the UK NHS reported 4.8 million outpatient appointments using NHS digital records systems (appointment volume figure)
02
In 2022, there were 7.9 million hospital day cases in the UK (activity volume figure)
03
In 2021–22, there were 33.1 million A&E attendances in England (activity count)
Interpretation
Operational Adoption Interpretation
Operational adoption is clearly scaling in the UK healthcare system, with digital records being used for 4.8 million outpatient appointments in 2023 alongside even larger activity volumes such as 7.9 million hospital day cases in 2022 and 33.1 million A&E attendances in England in 2021 to 22.
report visual · Comparison
DNA sequencing market: current scale vs near-term growth
The global DNA sequencing market is already substantial ($9.3B in 2023) and is projected to continue expanding (to $11.0B in 2024), supporting sustained demand across research and clinical workflows.
$11.0 billion 2024 global DNA sequencing market value, showing continued market expansion into the mid-2020s$11.0 billion
$9.3 billion 2023 global DNA sequencing market revenue, reflecting the sector’s current scale before forecast expansion
$9.3 billion
10.7% CAGR projected for the global DNA sequencing market during 2024–2032, indicating sustained growth from sequencing
10.7%
source-verifiedfortunebusinessinsights.com · researchandmarkets.com · globenewswire.com2024
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Dna Sequencing Industry Statistics. Gitnux. https://gitnux.org/dna-sequencing-industry-statistics
MLA
Diana Reeves. "Dna Sequencing Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dna-sequencing-industry-statistics.
Chicago
Diana Reeves. 2026. "Dna Sequencing Industry Statistics." Gitnux. https://gitnux.org/dna-sequencing-industry-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)